• JACC Asia - Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

  • Sep 3 2024
  • Length: 4 mins
  • Podcast

JACC Asia - Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Listen for free

View show details

  • Summary

  • In this episode of the JACC: Asia podcast, Dr. Magnus O. Wijkman reviews a pivotal study comparing the angiotensin receptor neprilysin inhibitor sacubitril alisarmin with olmesartan for treating primary hypertension in Chinese patients. The trial found sacubitril alisarmin to be more effective in reducing blood pressure and well-tolerated, suggesting its potential as a new option for hypertension treatment, though further long-term studies are needed.
    Show more Show less
activate_WEBCRO358_DT_T2
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show more Show less

What listeners say about JACC Asia - Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available